Red Queen Bio provides an AI‑driven platform that maps potential AI‑generated biothreats and automatically designs therapeutic countermeasures such as antibodies, antivirals, and vaccine antigens. The system integrates large‑scale protein language models, reinforcement‑learning optimization, and fully automated wet‑lab workflows with on‑demand biologics manufacturing, delivering ready‑to‑produce sequences via secure APIs and a web dashboard for biodefense agencies and biotech labs.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced generative AI models can autonomously design novel biological agents, creating a rapidly evolving threat landscape that outpaces traditional biodefense capabilities. Existing countermeasure development pipelines are labor‑intensive and tied to fixed funding cycles, limiting their ability to respond to emerging AI‑enabled biothreats. Consequently, there is a growing risk of unmitigated pathogenic breakthroughs that could have widespread public health impacts.
Solution
Red Queen Bio operates an AI‑driven biosecurity platform that continuously maps potential AI‑generated biothreats and pre‑engineers medical countermeasures. The core pipeline combines large‑scale protein‑language models with reinforcement learning to propose therapeutic candidates, then routes designs through fully automated wet‑lab workflows for synthesis, screening, and optimization. Results are streamed to a cloud‑native analytics layer that scales compute resources in line with threat complexity, ensuring defensive capability grows proportionally with offensive AI advances. Integrated on‑demand biologics manufacturing (e.g., mRNA, recombinant proteins) enables rapid production of validated countermeasures. The platform is offered through secure APIs and a web dashboard, allowing partner laboratories and government agencies to submit threat scenarios, monitor design progress, and retrieve ready‑to‑manufacture therapeutic sequences.
Target Audience
Primary customers are national biodefense agencies, biotech and biopharma R&D laboratories, and AI research groups that develop advanced biological models and require proactive countermeasure design capabilities.
Features
- Large‑scale protein and genome language models that generate plausible pathogenic designs for threat enumeration
- Reinforcement‑learning optimization loop that iterates therapeutic candidates (antibodies, antivirals, vaccine antigens) against simulated pathogen models
- High‑throughput robotic lab automation for DNA synthesis, expression, and functional screening, reducing wet‑lab cycle time from weeks to days
- Cloud‑native compute orchestration that elastically allocates GPU/TPU resources based on model complexity, enabling defensive co‑scaling
- Integrated on‑demand biologics manufacturing interface supporting mRNA, viral vector, and recombinant protein production pipelines
- Secure, encrypted data pipeline with role‑based access controls and compliance with relevant biosecurity regulations (e.g., BSL‑3 handling standards)
- RESTful API and web dashboard for partners to submit threat scenarios, track design status, and retrieve finalized therapeutic sequences in standard formats (FASTA, GenBank)